Translational Therapies for Mesothelioma

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis because of the poor response to all the treatments tested so far.

Most of the clinical trials run for this tumour have been based on drugs with some efficacy for other malignancies but without a specific background for MPM.

We reckon that this “random approach” is one of the most relevant reasons why the prognosis of these patients has been substantially unchanged from 2003 when the current front-line chemotherapy was approved.

Every step forward in therapy for human cancer has always been laid on the preclinical working ground, and thus we are firmly convinced the same workstream will generate more solid achievements for this neoplasm as well.

In the light of the most recent findings, tumour metabolism, immunometabolism and microenvironment will be particularly screened as new druggable targets

Therefore, we are asking some world-class groups known for working on innovative topics with the potential of being game-changers for MPM to provide us with their results and their understanding of the best direction to take in order to achieve better treatments for these patients.

Dr. Luciano Mutti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.